A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy

被引:8
|
作者
Gu, Linlin [1 ]
Krendelchtchikova, Valentina [1 ]
Krendelchtchikov, Alexandre [1 ]
Oster, Robert A. [2 ]
Fujihashi, Kohtaro [3 ]
Matthews, Qiana L. [1 ,4 ]
机构
[1] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Div Prevent Med, Dept Med, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Inst Oral Hlth Res, Immunobiol Vaccine Ctr, Dept Pediat Dent, Birmingham, AL 35294 USA
[4] Univ Alabama Birmingham, Ctr AIDS Res, Birmingham, AL 35294 USA
来源
VIROLOGY JOURNAL | 2014年 / 11卷
基金
美国国家卫生研究院;
关键词
Adenovirus (Ad); Human adenovirus (hAd); Antigen Capsid-Incorporation" strategy; HIV V3 loop; Humoral immune response; IgG isotype; Neutralization; CYTOTOXIC T-LYMPHOCYTES; PEPTIDE VACCINE; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; PROTECTIVE IMMUNITY; MOLECULAR ANALYSIS; PROMISING TARGETS; VIRAL VECTORS; GENE-THERAPY; AMINO-ACIDS;
D O I
10.1186/1743-422X-11-112
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Due to potential advantages, human adenoviral vectors have been evaluated pre-clinically as recombinant vaccine vectors against several cancers and infectious diseases, including human immunodeficiency virus (HIV) infection. The V3 loop of HIV-1 glycoprotein 120 (gp120) contains important neutralizing epitopes and plays key roles in HIV entry and infectivity. Methods: In order to investigate the humoral immune response development against portions of the V3 loop, we sought to generate four versions of adenovirus (Ad)-based V3 vectors by incorporating four different antigen inserts into the hypervariable region 1 (HVR1) of human adenovirus type 5 (hAd5) hexon. The strategy whereby antigens are incorporated within the adenovirus capsid is known as the "Antigen Capsid-Incorporation" strategy. Results: Of the four recombinant vectors, Ad-HVR1-Igs-His(6)-V3 and Ad-HVR1-long-V3 had the capability to present heterologous antigens on capsid surface, while maintaining low viral particle to infectious particle (VP/IP) ratios. The VP/IP ratios indicated both high viability and stability of these two vectors, as well as the possibility that V3 epitopes on these two vectors could be presented to immune system. Furthermore, both Ad-HVR1-Igs-His(6)-V3 and Ad-HVR1-long-V3 could, to some extent escape the neutralization by anti-adenovirus polyclonal antibody (PAb), but rather not the immunity by anti-gp120 (902) monoclonal antibody (MAb). The neutralization assay together with the whole virus enzyme-linked immunosorbent assay (ELISA) suggested that these two vectors could present V3 epitopes similar to the natural V3 presence in native HIV virions. However, subsequent mice immunizations clearly showed that only Ad-HVR1-Igs-His(6)-V3 elicited strong humoral immune response against V3. Isotype ELISAs identified IgG2a and IgG2b as the dominant IgG isotypes, while IgG1 comprised the minority. Conclusions: Our findings demonstrated that human adenovirus (hAd) vectors which present HIV antigen via the "Antigen Capsid-Incorporation" strategy could successfully elicit antigen-specific humoral immune responses, which could potentially open an avenue for the development of Ad-based HIV V3 vaccines.
引用
收藏
页数:11
相关论文
共 37 条
  • [21] Evaluation of the diagnostic efficiency of a recombinant antigen modeling the immunogenic epitope V3 of the envelope protein gp120 for immunoenzyme detection of antibodies to HIV-1
    S. A. Ryabinina
    E. N. Baranova
    I. N. Sharipova
    M. I. Susekina
    V. F. Puzyrev
    A. P. Obryadina
    A. N. Burkov
    T. I. Ulanova
    Molecular Genetics, Microbiology and Virology, 2007, 22 (3) : 127 - 130
  • [22] SYNERGISTIC NEUTRALIZATION OF HIV-1 BY HUMAN MONOCLONAL-ANTIBODIES AGAINST THE V3 LOOP AND THE CD4-BINDING SITE OF GP120
    TILLEY, SA
    HONNEN, WJ
    RACHO, ME
    CHOU, TC
    PINTER, A
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (04) : 461 - 467
  • [23] STUDIES ON IN-VIVO INDUCTION OF HIV-1 ENVELOPE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES BY SYNTHETIC PEPTIDES FROM THE V3 LOOP REGION OF HIV-1 IIIB GP120
    NEHETE, PN
    CASEMENT, KS
    ARLINGHAUS, RB
    SASTRY, KJ
    CELLULAR IMMUNOLOGY, 1995, 160 (02) : 217 - 223
  • [24] Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study
    Andrianov, Alexander M.
    Kashyn, Ivan A.
    Tuzikov, Alexander V.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2014, 32 (12): : 1993 - 2004
  • [25] RAPID PRESCREENING FOR ANTIVIRAL AGENTS AGAINST HIV-1 BASED ON THEIR INHIBITORY ACTIVITY IN SITE-DIRECTED IMMUNOASSAYS .2. PORPHYRINS REACTING WITH THE V3 LOOP OF GP120
    NEURATH, AR
    STRICK, N
    HABERFIELD, P
    JIANG, S
    ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1992, 3 (01): : 55 - 63
  • [26] MONITORING THE INTERACTION BETWEEN THE HIV-1 GP120 V3 LOOP AND THE N-TERMINAL CCR5 PEPTIDE CONSTRUCTS THROUGH NMR SPECTROSCOPY
    Galanakis, P.
    Spyroulias, G. A.
    Morikis, D.
    Rizos, A.
    Krambovitis, E.
    JOURNAL OF PEPTIDE SCIENCE, 2004, 10 : 271 - 271
  • [27] SYNERGISTIC NEUTRALIZATION OF HIV-1 BY MONOCLONAL-ANTIBODIES DIRECTED AGAINST THE V2 DOMAIN, V3 LOOP, AND CD4-BINDING SITE OF GP120
    TILLEY, SA
    VIJHWARRIER, S
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 227 - 227
  • [28] Thermodynamic analysis of the interaction between the 0.5 beta Fv fragment and the RP135 peptide antigen derived from the V3 loop of HIV-1 gp120
    Faiman, GA
    Horovitz, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (50) : 31407 - 31411
  • [29] Broadly reactive antibodies against a gp120 V3 loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1)
    Montero, M
    Menendez, A
    Dominguez, MD
    Navea, L
    Vilarubia, OL
    Quintana, D
    Izquierdo, M
    Jimenez, V
    Reyes, O
    Lobaina, L
    Noa, E
    Duarte, CA
    VACCINE, 1997, 15 (11) : 1200 - 1208
  • [30] Development of a single-shot subunit vaccine for HIV-1 .3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120
    Cleland, JL
    Barron, L
    Daugherty, A
    Eastman, D
    Kensil, C
    Lim, A
    Weissburg, RP
    Wrin, T
    Vennari, J
    Powell, MF
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (12) : 1350 - 1357